OBJECTIVES: To identify peripheral blood autoantibody and cytokine profiles that characterise clinically relevant subgroups of patients with early rheumatoid arthritis using arthritis antigen microarrays and a multiplex cytokine assay. METHODS: Serum samples from 56 patients with a diagnosis of rheumatoid arthritis of <6 months' duration were tested. Cytokine profiles were also determined in samples from patients with psoriatic arthritis (PsA) and ankylosing spondylitis (n = 21), and from healthy individuals (n = 19). Data were analysed using Kruskal-Wallis test with Dunn's adjustment for multiple comparisons, linear correlation tests, significance analysis of microarrays (SAM) and hierarchical clustering software. RESULTS: Distinct antibody profiles were associated with subgroups of patients who exhibited high serum levels of tumour necrosis factor (TNF)alpha, interleukin (IL)1beta, IL6, IL13, IL15 and granulocyte macrophage colony-stimulating factor. Significantly increased autoantibody reactivity against citrullinated epitopes was observed in patients within the cytokine "high" subgroup. Increased levels of TNFalpha, IL1alpha, IL12p40 and IL13, and the chemokines eotaxin/CCL11, monocyte chemoattractant protein-1 and interferon-inducible protein 10, were present in early rheumatoid arthritis as compared with controls (p<0.001). Chemokines showed some of the most impressive differences. Only IL8/CXCL8 concentrations were higher in patients with PsA/ankylosing spondylitis (p = 0.02). CONCLUSIONS: Increased blood levels of proinflammatory cytokines are associated with autoantibody targeting of citrullinated antigens and surrogate markers of disease activity in patients with early rheumatoid arthritis. Proteomic analysis of serum autoantibodies, cytokines and chemokines enables stratification of patients with early rheumatoid arthritis into molecular subgroups.
OBJECTIVES: To identify peripheral blood autoantibody and cytokine profiles that characterise clinically relevant subgroups of patients with early rheumatoid arthritis using arthritis antigen microarrays and a multiplex cytokine assay. METHODS: Serum samples from 56 patients with a diagnosis of rheumatoid arthritis of <6 months' duration were tested. Cytokine profiles were also determined in samples from patients with psoriatic arthritis (PsA) and ankylosing spondylitis (n = 21), and from healthy individuals (n = 19). Data were analysed using Kruskal-Wallis test with Dunn's adjustment for multiple comparisons, linear correlation tests, significance analysis of microarrays (SAM) and hierarchical clustering software. RESULTS: Distinct antibody profiles were associated with subgroups of patients who exhibited high serum levels of tumour necrosis factor (TNF)alpha, interleukin (IL)1beta, IL6, IL13, IL15 and granulocyte macrophage colony-stimulating factor. Significantly increased autoantibody reactivity against citrullinated epitopes was observed in patients within the cytokine "high" subgroup. Increased levels of TNFalpha, IL1alpha, IL12p40 and IL13, and the chemokines eotaxin/CCL11, monocyte chemoattractant protein-1 and interferon-inducible protein 10, were present in early rheumatoid arthritis as compared with controls (p<0.001). Chemokines showed some of the most impressive differences. Only IL8/CXCL8 concentrations were higher in patients with PsA/ankylosing spondylitis (p = 0.02). CONCLUSIONS: Increased blood levels of proinflammatory cytokines are associated with autoantibody targeting of citrullinated antigens and surrogate markers of disease activity in patients with early rheumatoid arthritis. Proteomic analysis of serum autoantibodies, cytokines and chemokines enables stratification of patients with early rheumatoid arthritis into molecular subgroups.
Authors: Wilco de Jager; Berent J Prakken; Johannes W J Bijlsma; Wietse Kuis; Ger T Rijkers Journal: J Immunol Methods Date: 2005-05 Impact factor: 2.303
Authors: Rosario García-Vicuña; Maria Victoria Gómez-Gaviro; Maria Jesús Domínguez-Luis; Martina K Pec; Isidoro González-Alvaro; Jose María Alvaro-Gracia; Federico Díaz-González Journal: Arthritis Rheum Date: 2004-12
Authors: E B Cook; J L Stahl; L Lowe; R Chen; E Morgan; J Wilson; R Varro; A Chan; F M Graziano; N P Barney Journal: J Immunol Methods Date: 2001-08-01 Impact factor: 2.303
Authors: Carol A Hitchon; Philip Alex; Lawrence B Erdile; Mark B Frank; Igor Dozmorov; Yuhong Tang; Keng Wong; Michael Centola; Hani S El-Gabalawy Journal: J Rheumatol Date: 2004-12 Impact factor: 4.666
Authors: Holden T Maecker; Tamsin M Lindstrom; William H Robinson; Paul J Utz; Matthew Hale; Scott D Boyd; Shai S Shen-Orr; C Garrison Fathman Journal: Nat Rev Rheumatol Date: 2012-05-31 Impact factor: 20.543
Authors: Jeremy Sokolove; Dannette S Johnson; Lauren J Lahey; Catriona A Wagner; Danye Cheng; Geoffrey M Thiele; Kaleb Michaud; Harlan Sayles; Andreas M Reimold; Liron Caplan; Grant W Cannon; Gail Kerr; Ted R Mikuls; William H Robinson Journal: Arthritis Rheumatol Date: 2014-04 Impact factor: 10.995
Authors: Xiaoyan Zhao; Ferhan Qureshi; P Scott Eastman; William C Manning; Claire Alexander; William H Robinson; Lyndal K Hesterberg Journal: J Immunol Methods Date: 2012-02-17 Impact factor: 2.303
Authors: Consuelo Romero-Sánchez; William H Robinson; Beren H Tomooka; John Londoño; Rafael Valle-Oñate; Feng Huang; Xiaohu Deng; Liyun Zhang; Chunhua Yang; David Tak Yan Yu Journal: Clin Rheumatol Date: 2008-06-20 Impact factor: 2.980
Authors: Lewis H Kuller; Rachel H Mackey; Brian T Walitt; Kevin D Deane; V Michael Holers; William H Robinson; Jeremy Sokolove; Yuefang Chang; Simin Liu; Christine G Parks; Nicole C Wright; Larry W Moreland Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995
Authors: Wolfgang Hueber; Beren H Tomooka; Franak Batliwalla; Wentian Li; Paul A Monach; Robert J Tibshirani; Ronald F Van Vollenhoven; Jon Lampa; Kazuyoshi Saito; Yoshiya Tanaka; Mark C Genovese; Lars Klareskog; Peter K Gregersen; William H Robinson Journal: Arthritis Res Ther Date: 2009-05-21 Impact factor: 5.156